Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.

NCT ID: NCT01929486

Last Updated: 2016-02-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 58 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-02-28

Brief Summary

The purpose of this study is to investigate safety, pharmacokinetics, effect of regulatory T cell depletion with Mogamulizumab for advanced or recurrent cancer patients.

Detailed Description

This study consists of phase Ia and Ib portions for patients with solid tumors.

Phase Ia portion is the standard 3+3 dose-escalation design with 0.1mg/kg, 0.5mg/kg and 1.0mg/kg of Mogamulizumab.

Phase Ib portion is the randomized study comparing 0.1mg/kg and tolerated dose of Mogamulizumab based on the phase Ia portion to pursue safer and immunologically more efficient dose.

Conditions

Solid Tumor

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

<Phase Ia> Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg

\<Phase Ia\> Dose-escalation method with Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg. Mogamulizumab will be administered 8 times every week.

Group Type: EXPERIMENTAL

Mogamulizumab

Intervention Type: BIOLOGICAL

Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.

<Phase Ib> Mogamulizumab of the tolerated dose

\<Phase Ib\> Mogamulizumab of the tolerated dose in Phase Ia will be administered 8 times every week.

Group Type: EXPERIMENTAL

Mogamulizumab

Intervention Type: BIOLOGICAL

Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.

<Phase Ib> Mogamulizumab 0.1mg/kg

\<Phase Ib\> Mogamulizumab 0.1mg/kg will be administered 8 times every week.

Group Type: EXPERIMENTAL

Mogamulizumab

Intervention Type: BIOLOGICAL

Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.

Interventions

Mogamulizumab

Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.

Intervention Type: BIOLOGICAL

Other Intervention Names

KW-0761

Eligibility Criteria

Inclusion Criteria

1. Patients with histologically confirmed, CCR4 negative lung, stomach, esophageal, ovarian or skin cancer.

2. Patients with therapy-resistant cancer. Patients with recurrent cancer or advanced cancer who refused standard therapies.

3. Eastern Cooperative Oncology Group (ECOG) Performance Status is 0, 1 or 2.

4. Patients should be 20 years or older at the time of informed consent.

5. No serious dysfunction of major organs (bone marrow, heart, lung, liver and kidney) and meet the following conditions ; 1) WBC count : >=1,500/mm3 2) Hemoglobin : >=8.0g/dL 3) Platelet count : >=75,000/mm3 4) Serum total bilirubin : <=2.0 x ULN 5) AST and ALT : <=2.5 x ULN (Patients with hepatic infiltration which is attributed to primary disease<=5.0 x ULN) 6) Serum creatinine : <=1.5 mg/dL 7) SpO2 : >=93 % 8) ECG : No abnormal findings. 9) EF : >=50 %

6. Agree to use birth control including condom etc. from the time of obtaining the first consent to 24 weeks after the final administration of the study drug (except female after menopause (1 year or more after the last menstruation) and female/male after the operation for sterilization).

7. Given written informed consent.

8. Patients who can be hospitalized from the day of first administration to the next day.

9. Patients who have target lesions measurable by RECIST ver.1.1.

10. Life expectancy >= 3 months.

Exclusion Criteria

1. Patients with HIV antibody positive.

2. Patients with HCV antibody positive.

3. Patients with autoimmune disease.

4. Patients with HBs antigen or HBV-DNA positive.

5. History of serious anaphylaxis induced by antibody preparation.

6. Patients with double cancer.

7. Within 4 weeks after treatment with anticancer agent, immune suppressant, immune enhancer, cytokine therapy, radiotherapy or surgery for the primary disease.

8. Pregnant or breast-feeding females and females who have a possibility of pregnancy.

9. Patients with active infection.

10. Patients with psychosis or dementia.

11. Patients who need continuous systemic administration of adrenocorticosteroid.

12. Patients who have received hematopoietic stem cell transplantation.

13. Patients who have presence or suspicion of CNS involvement.

14. Patients who are administered the other investigational product within 4 weeks of the entry.

15. Patients treated with immunotherapy for cancer (e.g. cancer vaccine therapy) within 12 weeks of the entry.

16. Any other inadequacy for this study.

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aichi Medical University

OTHER

Sponsor Role: lead

Responsible Party

Ryuzo Ueda, MD

Aichi Medical University

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Aichi Medical University

Nagoya, Aichi-ken, Japan

Countries

Japan

References

Fujikawa K, Saito T, Kurose K, Kojima T, Funakoshi T, Sato E, Kakimi K, Iida S, Doki Y, Oka M, Ueda R, Wada H. Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors. PLoS One. 2023 Sep 20;18(9):e0291772. doi: 10.1371/journal.pone.0291772. eCollection 2023.

Reference Type: DERIVED

PMID: 37729184 (View on PubMed)

Maeda Y, Wada H, Sugiyama D, Saito T, Irie T, Itahashi K, Minoura K, Suzuki S, Kojima T, Kakimi K, Nakajima J, Funakoshi T, Iida S, Oka M, Shimamura T, Doi T, Doki Y, Nakayama E, Ueda R, Nishikawa H. Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nat Commun. 2021 Dec 14;12(1):7280. doi: 10.1038/s41467-021-27574-0.

Reference Type: DERIVED

PMID: 34907192 (View on PubMed)

Other Identifiers

KW0761-IIT-01

Identifier Type: -

Identifier Source: org_study_id